Fig. 3: Impact of the anti-CD47 treatment on the production and maturation of RBCs in PV. | Leukemia

Fig. 3: Impact of the anti-CD47 treatment on the production and maturation of RBCs in PV.

From: Blocking the CD47-SIRPα interaction reverses the disease phenotype in a polycythemia vera mouse model

Fig. 3

A Gating strategy for the Lin-Sca-1 + c-Kit + (LSK) compartment and multipotent progenitors (MPPs), including long-term HSCs (HSCLT), short-term HSCs (HSCST), MPP2, MPP3, and MPP4. PV IgG1, n = 15; PV anti-CD47, n = 15. B LSK fraction determined in the bone marrow (BM) and spleen (SPL). C Composition of the LSK compartment and MPPs in PV mice treated with IgG1 or anti-CD47 determined by flow cytometry at terminal analysis in the BM (top) and SPL (bottom). D Gating strategy for erythroid differentiation. Proerythroblasts (I; FSChi CD44hi), basophilic erythroblasts (II; FSCint CD44hi), polychromatic erythroblasts (III; FSCint CD44int), orthochromatic erythroblasts (IV; FSClo CD44int), and erythroblasts (V; FSClo CD44-). WT IgG1, n = 4; WT anti-CD47, n = 4; PV IgG1, n = 15; PV anti-CD47, n = 15. E Percentages of erythroid progenitors in the BM (left) and SPL (right) (% of FSC CD44 out of CD11b-CD45.2-Ter119+) determined by flow cytometry at terminal analysis. Results are represented as mean ± standard deviation. ns not significant, *p < 0.05 (Kruskal–Wallis test with Dunn’s multiple comparisons for B (BM LSK fraction); two-way ANOVA with Tukey’s multiple comparisons test for B (SPL LSK fraction); unpaired student’s t-test or Mann–Whitney test for C).

Back to article page